A new Kaiser Health News database tracks campaign donations from drugmakers over the past 10 years.
Doctors who saw patients with a mysterious lung illness in the past suspected vaping as the cause but didn’t know where to report such cases.
Known as “authorized generics,” in-house spinoffs of brand-name drugs quietly undermine the competition.
The Food and Drug Administration released two decades of previously hidden data containing millions of injuries or malfunctions by medical devices. Here’s what we’ve learned so far.
The FDA reveals that 56,000 malfunctions associated with surgical staplers weren’t reported through its traditional public reporting system.
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
What to know about PBMs and rebates ahead of the Senate drug price hearing on — you guessed it — PBMs.
A KHN database shows that $58 million flowed from drugmakers to patient groups running national ads.
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven’t reached the market.
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
The Food and Drug Administration is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a KHN review of thousands of FDA documents — inspection records, recalls, warning letters and lawsuits — reveals how drugs that are poorly manufactured or contaminated can reach consumers.
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
One of the most popular electronic health records software systems used by hospitals, Epic Systems, can delete records or require cumbersome workarounds when clocks are set back for an hour, prompting many hospitals to opt for paper records for part of the night shift.
Drugmakers’ contributions to lawmakers have peaked as surging drug prices emerge as a hot-button political issue. In the past decade, Congress has received nearly $79 million from 68 pharma PACs, run by employees of companies that make drugs treating everything from cancer to erectile dysfunction.
The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
Kaiser Health News launches “Pre$cription for Power,” a groundbreaking database to expose Big Pharma’s ties to patient groups.
Researchers at the University of Southern California analyzed millions of prescriptions and concluded that close to a quarter paid copays that exceeded the cost of the drugs.
A KHN data analysis finds that the door of opportunities connecting Capitol Hill, the federal government and the drug industry likely spins in Big Pharma’s favor.
At a political rally in March, President Donald Trump said drug prices are “outrageous” and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.